As dendritic cells increasingly become the adjuvant of choice in new approaches to cancer immunotherapy, a degree of protocol standardization is required to aid future large-scale clinical trials.

LMU researchers have shown that a particular type of immune cell acts more flexibly than previously thought—with the ...